World Respiratory Disorders Market 2009-2024

1 Executive Summary
1.1 Aims of this Report
1.2 Brief Overview of the Chapters

2 Respiratory Diseases
2.1 Overview
2.2 Asthma
2.2.1 Causes and Triggers of Asthma
2.2.2 Increasing Prevalence
2.2.3 High Economic Costs
2.2.4 Treatments for Asthma
2.2.5 Delivery Method - the Inhaler
2.3 Chronic Obstructive Pulmonary Disease (COPD)
2.3.1 Symptoms of COPD
2.3.2 Management of COPD
2.3.3 COPD on the Rise
2.3.4 The Economic Burden of COPD
2.4 Upper Respiratory Infections
2.4.1 Cold
2.4.2 Influenza
2.4.3 Sinusitis
2.4.4 Pharyngitis/Tonsillitis
2.4.5 Allergic Rhinitis
2.5 Major Drug Classes in Treating Respiratory Diseases
2.5.1 Combination Drugs
2.5.2 Leukotriene Inhibitors
2.5.3 Corticosteroids
2.5.4 Beta-2 (Adrenoreceptor) Agonists
2.5.5 Antihistamines
2.5.6 Monoclonal Antibodies

3 World Market 2009-2024
3.1 Summary of Key Findings
3.2 Leading Company: GlaxoSmithKline
3.3 World Sales for Respiratory Disorder Drugs, 2009-2024
3.3.1 Combination Drugs: The Most Successful Category
3.3.2 Corticosteroids
3.3.3 Antihistamines Face Major Challenges
3.3.4 Leukotriene Inhibitors: the Dominance of Singulair
3.3.5 Beta-2 Agonists: the Safety Concerns
3.3.6 Monoclonal Antibodies: Safe from Patent Expiry?
3.4 Increased Competition

4 Combination Drugs: The World Market 2009-2024
4.1 Leading the Market
4.2 GlaxoSmithKline's Advair/Seretide
4.2.1 Three Major Challenges
4.3 Symbicort: Facing Strong Competition
4.3.1 Aiming for a New Market
4.3.2 The COPD Indication
4.3.3 The SMART Concept
4.4 Combivent: Will It Reach Blockbuster Status?
4.5 Will the Leading Position Last?

5 Corticosteroids: The World Market 2009-2024
5.1 AstraZeneca's Pulmicort Leads the Market
5.1.1 Delivery Methods
5.1.2 Challenges for Pulmicort: Are They Insurmountable?
5.2 Nasonex/Asmanex on the Rise
5.3 Flovent/Flixotide - Reached its Peak?
5.4 Will Sales of Corticosteroids Continue to Increase?

6 Leukotriene Inhibitors: The World Market 2009-2024
6.1 Singulair
6.1.1 Competitors from Other Drug Categories
6.1.2 Side Effects

7 Beta-2 Agonists: The World Market 2009-2024
7.1 Sepracor's Xopenex at the Top
7.1.1 Challenges and Competitors
7.2 Teva's Salamol and GlaxoSmithKline's Ventolin
7.3 Safety Issues and Potential Loss of Market Share
7.4 Summary

8 Antihistamines: The World Market 2009-2024
8.1 Clarinex/Aerius Leads the Market
8.1.1 Challenges for Clarinex
8.2 Sanofi-Aventis' Allegra/Telfast
8.2.1 Competition and OTC Availability
8.3 Zyrtec and Patent Expiry
8.4 The Future for Antihistamines

9 Monoclonal Antibodies: The World Market 2009-2024
9.1 Synagis: the Sole Blockbuster?
9.1.1 Numax: A Follow-On Product
9.2 Xolair Shows Steady Growth
9.3 Biologicals vs. Chemically-Derived Pharmaceutical Products: the Advantages of Biologicals
9.4 A Promising Future

10 Other Key Products: The World Market 2009-2024
10.1 Boehringer Ingelheim's Spiriva
10.1.1 Safety Concerns and the UPLIFT Trial
10.1.2 Competition and Other Restraints
10.2 Wyeth's Prevnar
10.2.1 Competition and Development
10.3 Roche's Tamiflu
10.3.1 The Avian Flu Scare
10.3.2 Consequences of the 2009 Swine Flu Outbreak
10.3.3 Competition for Tamiflu
10.4 Influenza Vaccines

11 SWOT Analysis of the Respiratory Market
11.1 Principal Drivers for Respiratory Therapeutics
11.1.1 Expanding Patient Populations
11.1.2 High Economic Cost of Respiratory Diseases
11.1.3 Changing Views of Respiratory Disorders
11.1.4 Educating the Masses: Understanding the Severity of Respiratory Diseases
11.1.5 Management Rather than Cure
11.1.6 Lifecycle Management Strategies to Counter Patent Expiry
11.1.7 Brand Awareness
11.2 Principal Restraints for Respiratory Therapeutics
11.2.1 The Threat of Generics
11.2.2 Restrictions on Healthcare Costs Favour the Use of Generics
11.2.3 Purchasers Hold Increased Bargaining Power
11.2.4 Maturation of the Overall Market – How Much of a Challenge?
11.3 Summary of Market Drivers and Restraints

12 Geographical Breakdown of the Market
12.1 USA
12.2 Europe
12.3 Emerging markets
12.3.1 Russia
12.3.2 China
12.3.3 India

13 The Respiratory Pipeline
13.1 The Lucrative COPD Market
13.1.1 Products to Watch
13.2 Early Assessment of Asthma
13.3 Biologicals
13.3.1 Monoclonal Antibodies
13.3.2 Products to Watch
13.4 Influenza Treatments
13.4.1 Towards a Universal Influenza Vaccine
13.4.2 Products to Watch

14 Expert Opinions
14.1 Dr Janice Reichert
14.1.1 The Threat of Biosimilars
14.1.2 Further Developmental Trends
14.2 Dr Michael Watson
14.2.1 Influenza Vaccines Containing M2e
14.2.2 The Threat of Mutation

15 Conclusions
15.1 High Revenues
15.2 Potential for Growth in Emerging Markets
15.3 Potential for Growth Through Addressing Unmet Needs
15.4 Will Combination Drugs Continue to Dominate?
15.5 Future Opportunities for Monoclonal Antibodies
15.6 The Road Ahead

List of Tables
Table 2.1 Respiratory Diseases
Table 2.2 Causes of Asthma
Table 2.3 Asthma Triggers
Table 2.4 Symptoms of COPD
Table 2.5 Leading Causes of Death, 2004 and 2030
Table 2.6 Symptoms for Upper Respiratory Infections
Table 2.7 Month, Year, and Country of Human Avian Flu Cases, January 08-March 09
Table 3.1 Market Share (%) of the Leading Companies in the Respiratory Therapeutic Area, 2008
Table 3.2 Sales ($m) for the World Respiratory Disorder Market, 2009-2024
Table 3.3 Drug Categories, World Sales ($m) and Market Share (%), 2008 and 2014
Table 3.4 Key Products in the Respiratory Disorder Therapeutic Area, World Sales ($m) and Market Share (%), 2008
Table 4.1 Combination Drugs, Key Products World Sales ($m), 2008-2014
Table 4.2 Combination Drugs, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 5.1 Corticosteroids, Key Products World Sales ($m), 2008-2014
Table 5.2 Corticosteroids, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 6.1 Leukotriene Inhibitors, World Sales ($m), 2008-2014
Table 6.2 Leukotriene Inhibitors, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 7.1 Beta-2 Agonists, Key Products World Sales ($m), 2008-2014
Table 7.2 Beta-2 Agonists, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 8.1 Antihistamines, Key Products World Sales ($m), 2008-2014
Table 8.2 Antihistamines, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 9.1 Monoclonal Antibodies, Key Products World Sales ($m), 2008-2014
Table 9.2 Monoclonal Antibodies, Key Products World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 10.1 Other Key Products, World Sales ($m), 2008-2014
Table 10.2 Symptoms of Swine Flu
Table 10.3 Influenza vaccines, World Sales ($m), 2008-2014
Table 10.4 Influenza Vaccines, World Sales ($m), CAGR (%) and Market Share (%), 2009, 2014, 2019 and 2024
Table 11.1 SWOT Analysis for the Respiratory Market, 2009
Table 12.1 Sales ($m), CAGR (%) and Market Share (%) for Key Geographical Markets, 2008, 2014, 2019 and 2024

List of Figures
Figure 3.1 Market Share (%) of the Leading Companies in the Respiratory Therapeutic Area, 2008
Figure 3.2 Sales ($m) for the World Market, 2009-2024
Figure 3.3 Market Share (%) of Key Drug Categories in the Respiratory Market, 2008
Figure 4.1 Sales ($m) for Combination Drugs, 2008-2024
Figure 4.2 Sales ($m) for Advair/Seretide, 2008-2024
Figure 4.3 Key Products Marked Share (%) Within the Combination Drug Category, 2008
Figure 4.4 Sales ($m) for Symbicort, 2008-2024
Figure 4.5 Sales ($m) for Combivent, 2008-2024
Figure 4.6 Sales ($m) of Key Products in the Combination Drug Category, 2009, 2014, 2019 and 2024
Figure 5.1 Sales ($m) for Corticosteroids, 2008-2024
Figure 5.2 Key Product Market Share (%) within the Corticosteroid Category, 2008
Figure 5.3 Sales ($m) for Pulmicort, 2008-2024
Figure 5.4 Sales ($m) for Nasonex, 2008-2024
Figure 5.5 Sales ($m) for Flovent, 2008-2024
Figure 5.6 Sales ($m) of Key Products in the Corticosteroid Category, 2009, 2014, 2019 and 2024
Figure 6.1 Sales ($m) for Leukotriene Inhibitors, 2008-2024
Figure 6.2 Leukotriene Inhibitors, Market Share (%), 2008
Figure 6.3 World Sales ($m) of Singulair, 2008-2024
Figure 6.4 Sales ($m) of Key Products in the Corticosteroid Category, 2009, 2014, 2019 and 2024
Figure 7.1 Sales ($m) for Beta-2 Agonists, 2008-2024
Figure 7.2 Key Products Marked Share (%) Within the Beta-2 Agonist Category, 2008
Figure 7.3 Sales ($m) of Xopenex, 2008-2024
Figure 7.4 Sales ($m) of Salamol, 2008-2024
Figure 7.5 Sales ($m) of Ventolin, 2008-2024
Figure 7.6 Sales ($m) of Key Products in the Beta-2 Agonists Category, 2009, 2014, 2019 and 2024
Figure 8.1 Sales ($m) for Antihistamines, 2008-2024
Figure 8.2 Antihistamines Market Share (%), 2008
Figure 8.3 Sales ($m) for Clarinex, 2008-2024
Figure 8.4 Sales ($m) for Allegra, 2008-2024
Figure 8.5 Sales ($m) for Zyrtec, 2008-2024
Figure 8.6 Sales ($m) of Key Products in the Antihistamine Category, 2009, 2014, 2019 and 2024
Figure 9.1 Sales ($m) for Monoclonal Antibodies, 2008-2024
Figure 9.2 Key Product Market Share (%) within the Monoclonal Antibody Category, 2008
Figure 9.3 Sales ($m) for Synagis, 2008-2024
Figure 9.4 Sales ($m) of Key Products in the Monoclonal Antibody Category, 2009, 2014, 2019 and 2024
Figure 9.5 Sales ($m) for Xolair, 2008-2024
Figure 10.1 Sales ($m) for Spiriva, 2008-2024
Figure 10.2 Sales ($m) for Prevnar, 2008-2024
Figure 10.3 Sales ($m) for Tamiflu, 2008-2024
Figure 10.4 Sales ($m) for Influenza Vaccines, 2008-2024
Figure 12.1 Market Share (%) for Key Geographical Regions, 2008
Figure 12.2 Sales ($m) for the Respiratory Markets in the US, Europe and E7 Countries, 2009, 2014, 2019 and 2024